Literature DB >> 12458963

Pleiotropic mechanisms of ribavirin antiviral activities.

Zhi Hong1, Craig E Cameron.   

Abstract

Renewed interest in the mechanism of action of ribavirin results from its synergistic enhancement of interferon therapy and the need to develop more efficacious agents to treat hepatitis C virus infection. Since the discovery of ribavirin over 30 years ago by scientists at ICN Pharmaceuticals, many mechanisms of action for ribavirin have been proposed. These include inhibition of host inosine monophosphate dehydrogenase by ribavirin monophosphate, inhibition of viral capping enzymes, inhibition of viral RNA synthesis by ribavirin triphosphate, lethal mutagenesis of viral RNA genomes resulting from promiscuous incorporation of ribavirin triphosphate by the viral RNA polymerase, and modulation of the host immune responses. In this article, we will briefly review the evidence for these mechanisms, emphasizing recent findings. In addition, we will discuss strategies for development of nucleoside analogs that may replace ribavirin in the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458963     DOI: 10.1007/978-3-0348-8171-5_2

Source DB:  PubMed          Journal:  Prog Drug Res        ISSN: 0071-786X


  24 in total

Review 1.  Further evidence that ribavirin interacts with eIF4E.

Authors:  Alex Kentsis; Laurent Volpon; Ivan Topisirovic; Clifford E Soll; Biljana Culjkovic; Ling Shao; Katherine L B Borden
Journal:  RNA       Date:  2005-10-26       Impact factor: 4.942

Review 2.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

3.  A broad-spectrum antiviral targeting entry of enveloped viruses.

Authors:  Mike C Wolf; Alexander N Freiberg; Tinghu Zhang; Zeynep Akyol-Ataman; Andrew Grock; Patrick W Hong; Jianrong Li; Natalya F Watson; Angela Q Fang; Hector C Aguilar; Matteo Porotto; Anna N Honko; Robert Damoiseaux; John P Miller; Sara E Woodson; Steven Chantasirivisal; Vanessa Fontanes; Oscar A Negrete; Paul Krogstad; Asim Dasgupta; Anne Moscona; Lisa E Hensley; Sean P Whelan; Kym F Faull; Michael R Holbrook; Michael E Jung; Benhur Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-28       Impact factor: 11.205

Review 4.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

Review 5.  A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Authors:  Girish S Naik; Manoj G Tyagi
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

6.  The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.

Authors:  Pieter Leyssen; Jan Balzarini; Erik De Clercq; Johan Neyts
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Triaryl pyrazoline compound inhibits flavivirus RNA replication.

Authors:  Francesc Puig-Basagoiti; Mark Tilgner; Brett M Forshey; Sean M Philpott; Noel G Espina; David E Wentworth; Scott J Goebel; Paul S Masters; Barry Falgout; Ping Ren; David M Ferguson; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  Successful fertility restoration after allogeneic hematopoietic stem cell transplantation.

Authors:  Helen Gharwan; Nicola M Neary; Mary Link; Matthew M Hsieh; Courtney D Fitzhugh; Richard J Sherins; John F Tisdale
Journal:  Endocr Pract       Date:  2014-09       Impact factor: 3.443

Review 9.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

10.  Sultam thiourea inhibition of West Nile virus.

Authors:  Eric Barklis; Amelia Still; Mohammad I Sabri; Alec J Hirsch; Janko Nikolich-Zugich; James Brien; Tenzin Choesang Dhenub; Isabel Scholz; Ayna Alfadhli
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.